But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Rather than training the algorithm on content scraped from the internet, scientists trained the AI on nearly three million genomes.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

Ken Hawkins, a retired teacher from Grants Pass, is first Oregon participant in phase 3 clinical trial Ken Hawkins, a 77-year ...

A virologist named Beata Halassy recently made headlines after publishing a report of successfully treating her own breast ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

The invasive sea lamprey was chomping through the North American region’s native fish, until scientists made a fortuitous ...